AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10682561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nylestriol
Number of subjects: 36
Study 10682561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7619643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through heterosexual transmission
Number of subjects: 260
Study 7619643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through homosexual transmission
Number of subjects: 260
Study 7619643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through needle-sharing
Number of subjects: 260
Study 7619643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture by a person with AIDS (PWA) revealing HIV positive status through blood transfusion
Number of subjects: 260
Study 7619643 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neutral presenter with no HIV status disclosure)
Number of subjects: 260
Study 7619643 — intervention group
Group type: COMPARATOR
Intervention: No contact (control condition)
Number of subjects: 260
Study 2526866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 1 mmol.kg‐1.day‐1
Number of subjects: 20
Study 2526866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium intake of 3 mmol.kg‐1.day‐1
Number of subjects: 20
Study 2526866 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1 and 3 mmol.kg‐1.day‐1)
Number of subjects: 20
Study 1082365 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule 1: single intravenous push of cytosine arabinoside followed by oral methotrexate and intravenous vincristine, cycle repeated every 7 days.
Number of subjects: 98
Study 1082365 — intervention group
Group type: COMPARATOR
Intervention: Schedule 2: three daily injections of cytosine arabinoside followed by vincristine and methotrexate, cycle repeated every 10 days.
Number of subjects: 98
Study 30551218 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant users
Number of subjects: 42890
Study 30551218 — intervention group
Group type: EXPERIMENTAL
Intervention: No use of antidepressants before IBD onset
Number of subjects: 42890
Study 30551218 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of antidepressants
Number of subjects: 42890
Study 30060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (8 mL injected)
Number of subjects: 39
Study 30060719 — intervention group
Group type: COMPARATOR
Intervention: Oral pain medication alone (Control)
Number of subjects: 39
Study 27389019 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids and Keto-Analogues (EAA/KA) supplementation with low protein diet (LPD)
Number of subjects: 96
Study 27389019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EAA/KA supplementation)
Number of subjects: 96
Study 24730361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL/kg of 24% sucrose with a pacifier
Number of subjects: 64
Study 24730361 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL/kg of sterile water with a pacifier
Number of subjects: 64
Study 22929989 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (EOM)
Number of subjects: 34
Study 22929989 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse (P)
Number of subjects: 34
Study 20585813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous DEX 0.3 μg kg⁻¹
Number of subjects: 81
Study 20585813 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 81
Study 17507354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease present
Number of subjects: 146
Study 17507354 — intervention group
Group type: COMPARATOR
Intervention: Chronic kidney disease absent
Number of subjects: 146
Study 17507354 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or appropriate ICD therapy
Number of subjects: 146
Study 17507354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac death
Number of subjects: 146
Study 15731473 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 400
Study 15731473 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 400
Study 12484432 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride
Number of subjects: 0
Study 12484432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9809861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (12.5 mg morning and mid-day, 25 mg evening)
Number of subjects: 244
Study 9809861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three capsules/day)
Number of subjects: 244
Study 9809861 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg morning and mid-day, 10 mg evening)
Number of subjects: 244
Study 7666097 — intervention group
Group type: EXPERIMENTAL
Intervention: ChlVPP/EVA hybrid regimen
Number of subjects: 423
Study 2711309 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (15 mg/kg) administered intravenously shortly before surgery completion and 5‐6 mg/kg/day in three divided doses for the first 3 postoperative days.
Number of subjects: 189
Study 2711309 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered under identical conditions to the control group of 185 patients.
Number of subjects: 189
Study 598405 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine 30 mg
Number of subjects: 12
Study 598405 — intervention group
Group type: COMPARATOR
Intervention: furosemide 40 mg
Number of subjects: 12
Study 31377052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg Q2W
Number of subjects: 4983
Study 31377052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 4983
Study 31377052 — intervention group
Group type: COMPARATOR
Intervention: Control (ezetimibe + statin)
Number of subjects: 4983
Study 31377052 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo + statin)
Number of subjects: 4983
Study 31377052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983
Study 28732209 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education program on combating violence against women
Number of subjects: 136
Study 28732209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer education)
Number of subjects: 136
Study 26310577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tackling Teenage Training (TTT) program
Number of subjects: 200
Study 26310577 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 200
Study 23248207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve cryoanalgesia (INC)
Number of subjects: 160
Study 23248207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-divided intercostal muscle flap (NIMF)
Number of subjects: 160
Study 21270655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes of exercise five days a week
Number of subjects: 132
Study 21270655 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 minutes of exercise five days a week
Number of subjects: 132
Study 21270655 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer exercise program (12 minutes)
Number of subjects: 132
Study 18443989 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritually based educational booklet
Number of subjects: 108
Study 18443989 — intervention group
Group type: COMPARATOR
Intervention: Secular educational booklet
Number of subjects: 108
Study 17056939 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% carbohydrate drink (CHO)
Number of subjects: 188
Study 17056939 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored water (placebo)
Number of subjects: 188
Study 17056939 — intervention group
Group type: COMPARATOR
Intervention: Fasting overnight (control)
Number of subjects: 188
Study 12609561 — intervention group
Group type: EXPERIMENTAL
Intervention: CR BNO 1055 (daily dose corresponding to 40 mg herbal drug)
Number of subjects: 62
Study 12609561 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.6 mg)
Number of subjects: 62
Study 12609561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12609561 — intervention group
Group type: EXPERIMENTAL
Intervention: CR BNO 1055
Number of subjects: 62
Study 10636491 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus zidovudine
Number of subjects: 16
Study 10636491 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus stavudine
Number of subjects: 16
Study 10636491 — intervention group
Group type: COMPARATOR
Intervention: lamivudine plus zidovudine or stavudine
Number of subjects: 16
Study 8873431 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 155
Study 8873431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 7911271 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release nisoldipine (20 mg twice daily)
Number of subjects: 44
Study 7911271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2821477 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental rotavirus vaccine
Number of subjects: 50
Study 2821477 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 children)
Number of subjects: 50
Study 29436142 — intervention group
Group type: EXPERIMENTAL
Intervention: AXOS (9.4 g)
Number of subjects: 13
Study 29436142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g maltodextrin + 1 g unlabelled lactose ureide)
Number of subjects: 13
Study 24621126 — intervention group
Group type: EXPERIMENTAL
Intervention: Active charcoal filter
Number of subjects: 30
Study 24621126 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard particle filter
Number of subjects: 30
Study 24621126 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered DE
Number of subjects: 30
Study 24621126 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 30
Study 24621126 — intervention group
Group type: COMPARATOR
Intervention: Diesel exhaust PM
Number of subjects: 30
Study 22807538 — intervention group
Group type: EXPERIMENTAL
Intervention: MATI protocol
Number of subjects: 225
Study 22807538 — intervention group
Group type: COMPARATOR
Intervention: Conventional (non-MATI) clinical follow-up
Number of subjects: 225
Study 20430253 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication plus ferrous sulfate supplementation
Number of subjects: 72
Study 20430253 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 72
Study 20430253 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate supplementation (noninfected children)
Number of subjects: 72
Study 18712409 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with alanyl-glutamine dipeptide (Gln)
Number of subjects: 70
Study 18712409 — intervention group
Group type: COMPARATOR
Intervention: Regular parenteral nutrition (Control)
Number of subjects: 70
Study 15759218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice (MP) protocol
Number of subjects: 11
Study 15759218 — intervention group
Group type: COMPARATOR
Intervention: Relaxation techniques (Control)
Number of subjects: 11
Study 12660668 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1: Hospital charges
Number of subjects: 1849
Study 12660668 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2: Hospital charges converted to costs using hospital-level cost-to-charge ratios
Number of subjects: 1849
Study 12660668 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3: Hospital charges converted to costs using department-level cost-to-charge ratios
Number of subjects: 1849
Study 12660668 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 4: Itemized catheterization laboratory costs with nonprocedural hospital costs from department-level cost-to-charge ratios
Number of subjects: 1849
Study 10555930 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐571
Number of subjects: 8
Study 10555930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7675582 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining procedure
Number of subjects: 46
Study 7675582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breathing process)
Number of subjects: 46
Study 1980542 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment under open conditions
Number of subjects: 17
Study 1980542 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment under double-blind conditions
Number of subjects: 17
Study 1980542 — intervention group
Group type: COMPARATOR
Intervention: Placebo under double-blind conditions
Number of subjects: 17
Study 7448103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.01 mg kg‐1
Number of subjects: 80
Study 7448103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.015 mg kg‐1
Number of subjects: 80
Study 7448103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.02 mg kg‐1
Number of subjects: 80
Study 7448103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine 0.3 mg kg‐1
Number of subjects: 80
Study 31657021 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 381
Study 31657021 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 381
Study 31510871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 149
Study 31510871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexmedetomidine 0.5 μg/kg and dexamethasone 5 mg
Number of subjects: 149
Study 31510871 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 149
Study 28371868 — intervention group
Group type: EXPERIMENTAL
Intervention: Press tack needles
Number of subjects: 60
Study 28371868 — intervention group
Group type: COMPARATOR
Intervention: Press tack placebos
Number of subjects: 60
Study 28371868 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy including classical needle acupuncture
Number of subjects: 60
Study 28371868 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy without classical needle acupuncture
Number of subjects: 60
Study 26178727 — intervention group
Group type: COMPARATOR
Intervention: Biofortified maize intervention
Number of subjects: 140
Study 23696281 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 86
Study 20694473 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision (Balafilcon A)
Number of subjects: 20
Study 20694473 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity (Comfilcon A)
Number of subjects: 20
Study 19037756 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mg Polaprezinc daily for 12 weeks
Number of subjects: 109
Study 19037756 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 mg Polaprezinc daily for 12 weeks
Number of subjects: 109
Study 19037756 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 mg Polaprezinc daily for 12 weeks
Number of subjects: 109
Study 19037756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 17097523 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention (mailing DXA scan results + call from nurse educator)
Number of subjects: 56
Study 17097523 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 15251273 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/16 h nicotine patches (Nicorette)
Number of subjects: 36
Study 15251273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11371413 — intervention group
Group type: EXPERIMENTAL
Intervention: O(3) > 80 ppb
Number of subjects: 24
Study 11371413 — intervention group
Group type: EXPERIMENTAL
Intervention: NQO1wt and GSTM1null subjects
Number of subjects: 24
Study 11371413 — intervention group
Group type: EXPERIMENTAL
Intervention: Other haplotypes
Number of subjects: 24
Study 11371413 — intervention group
Group type: EXPERIMENTAL
Intervention: O(3) exposure
Number of subjects: 24
Study 9209767 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 73
Study 7936730 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic upon onset of sensation
Number of subjects: 0
Study 7936730 — intervention group
Group type: COMPARATOR
Intervention: Analgesic upon onset of pain
Number of subjects: 0
Study 2975448 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5, 5, 10, or 20 micrograms dose of recombinant yeast-derived hepatitis B vaccine
Number of subjects: 220
Study 2975448 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms dose of plasma-derived vaccine
Number of subjects: 220
Study 2975448 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms booster dose of recombinant vaccine
Number of subjects: 220
Study 31838010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg once daily for 3 weeks on, 1 week off) plus daily letrozole (2·5 mg/day) for 24 weeks
Number of subjects: 106
Study 31838010 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days followed by weekly paclitaxel 80 mg/m2 for 12 weeks) for 24 weeks
Number of subjects: 106
Study 31838010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 106
Study 31838010 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 106
Study 29674370 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g dose of cephalexin administered 40‐60 min prior to surgery
Number of subjects: 154
Study 29674370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 28339576 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment e-cigarette users
Number of subjects: 217
Study 28339576 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 217
Study 25261492 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 2299
Study 25261492 — intervention group
Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 2299
Study 22958160 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (Phaco)
Number of subjects: 67
Study 22958160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and viscogonioplasty (Phaco‐VGP)
Number of subjects: 67
Study 20375805 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvanted vaccine
Number of subjects: 1040
Study 20375805 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Control)
Number of subjects: 1040
Study 18339475 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen suppression (CAS)
Number of subjects: 129
Study 18339475 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematically interrupted androgen suppression (SIAS)
Number of subjects: 129
Study 18339475 — intervention group
Group type: COMPARATOR
Intervention: Both CAS and SIAS
Number of subjects: 129
Study 16988140 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention (home visits and group meetings for 12 months)
Number of subjects: 107
Study 16988140 — intervention group
Group type: COMPARATOR
Intervention: Control group (undernourished children without psychosocial stimulation)
Number of subjects: 107
Study 16988140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervened children (psychosocial stimulation)
Number of subjects: 107
Study 14753593 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic injection protocol (123 mL at 2.5 mL/s)
Number of subjects: 60
Study 14753593 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic injection protocol (123 mL, 60 mL at 1.5 mL/s and then 63 mL at 2.5 mL/s)
Number of subjects: 60
Study 14753593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoid injection protocol (0.6 mL/s ending at 2.5 mL/s)
Number of subjects: 60
Study 10793867 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 23
Study 10793867 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 23
Study 8632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Number of subjects: 0
Study 8632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse whole meal rye bread diet
Number of subjects: 0
Study 8632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine whole meal rye bread diet
Number of subjects: 0
Study 1600772 — intervention group
Group type: EXPERIMENTAL
Intervention: Greatest response-invoking agent (specific agent not mentioned)
Number of subjects: 18
Study 1600772 — intervention group
Group type: COMPARATOR
Intervention: Least response-invoking agent (specific agent not mentioned)
Number of subjects: 18
Study 6383836 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 99
Study 6383836 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study 30952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 76
Study 30952581 — intervention group
Group type: COMPARATOR
Intervention: Active control tVNS
Number of subjects: 76
Study 30204239 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone (ELd)
Number of subjects: 0
Study 30204239 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Ld)
Number of subjects: 0
Study 26310842 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item German short version of the Örebro Musculoskeletal Pain Questionnaire (ÖMSPQ)
Number of subjects: 360
Study 26310842 — intervention group
Group type: EXPERIMENTAL
Intervention: ÖMSPQ subscales on pain related disability, depression, and fear-avoidance beliefs
Number of subjects: 360
Study 25253665 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPO-5 (250 μg)
Number of subjects: 174
Study 25253665 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452) alone
Number of subjects: 174
Study 25253665 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452) + LIPO-5 (250, 750, and 2,500 μg)
Number of subjects: 174
Study 25253665 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452) + LIPO-5
Number of subjects: 174
Study 25253665 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 174